{
  "id": 3384534,
  "title": "A cancer vaccine is closer than ever",
  "url": "https://urgent.news/2026/08/26/a-cancer-vaccine-is-closer-than-ever",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-26T00:32:03.000Z",
  "source": {
    "name": "The Korea Times",
    "slug": "the-korea-times-koreatimes",
    "url": "https://www.koreatimes.co.kr/opinion/20260826/a-cancer-vaccine-is-closer-than-ever"
  },
  "original_language": "en",
  "account": "Scientists may be on the verge of a long-awaited breakthrough: utilizing vaccines to train the immune system to identify and eliminate cancer cells. The application of an mRNA cancer vaccine, developed by Merck & Co. and Moderna Inc., has shown promise in a large, late-stage trial, effectively preventing melanoma from recurring. This marks a significant milestone for a technology that has faced numerous setbacks over the years, including political opposition following the pandemic and repeated false starts.\n\nFor over a century, the idea of cancer vaccines has captured the interest of researchers, with headlines promising potential treatments in the past two decades. However, none of these efforts have ultimately proven successful. Coaxing the body to combat its own cells has proven to be an exceedingly challenging task. The recent advancements in mRNA technology are now enabling researchers to move beyond the initial \"hope\" and \"promise\" phase.\n\nMerck & Moderna's Phase 3 study, involving the personalized mRNA-based vaccine intismeran alongside the immunotherapy Keytruda, provides compelling evidence that cancer vaccines can indeed be effective. Although further research is needed to demonstrate their potential applicability to various types of cancer, this development brings us one step closer to a groundbreaking treatment.",
  "summary": "Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts…",
  "key_points": [
    "Merck & Moderna's mRNA cancer vaccine shows promise in preventing melanoma recurrence",
    "Phase 3 study with personalized vaccine and Keytruda demonstrates vaccine effectiveness",
    "Significant milestone for cancer vaccine technology after years of setbacks"
  ],
  "editors_take": "This breakthrough in mRNA cancer vaccine technology marks a significant shift in cancer treatment, offering a promising approach to preventing cancer recurrence and potentially expanding treatment options.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Korea Times",
        "title": "A cancer vaccine is closer than ever",
        "url": "https://urgent.news/2026/08/26/a-cancer-vaccine-is-closer-than-ever-3390115",
        "published": "2026-08-26T01:07:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}